NEW DELHI – The Indian drug pricing regulator is caught in a bitter wrangle between the pharmaceutical industry and public health organizations over recent and contradictory government orders that first called for a cap on drug prices and then U-turned.
NEW DELHI – The Indian drug pricing regulator is caught in a bitter wrangle between the pharmaceutical industry and public health organizations over recent and contradictory government orders that first called for a cap on drug prices and then U-turned.
NEW DELHI – A recent acquisition by a leading Indian biotech company could spur drug development and clinical trials for treatments for brain and central nervous system diseases. The incidence of both ailments is on the rise.
NEW DELHI – India's drug pricing regulator has withdrawn a series of guidelines that capped prices of diabetes, cardiovascular disease and asthma drugs.
NEW DELHI – A recent acquisition by a leading Indian biotech company could spur drug development and clinical trials for treatments for brain and central nervous system diseases. The incidence of both ailments is on the rise.
NEW DELHI – India's drug pricing regulator has withdrawn a series of guidelines that capped prices of diabetes, cardiovascular disease and asthma drugs. The sudden U-turn in policy was timed ahead of a recent visit by Indian Prime Minister Narendra Modi to the U.S. and has sharply divided the pharmaceutical industry that welcomes the move and public health analysts that oppose it.
NEW DELHI – An Indian biotechnology company with headquarters in Pennsylvania and best known for its urology and testosterone therapies is looking to overcome a series of reverses through a $75 million restructuring and a merger with a Canadian company.
NEW DELHI – The Indian biotech firm Biocon Ltd. plans to buy back a stake in its research unit, Syngene, now held by GE Capital. The rapidly growing subsidiary represents more than a quarter of Biocon's revenues. The move, which will cost $35.5 million, is part of Biocon's restructuring of its R&D infrastructure, which will see some activities moved out of India.
